Lifecore Biomedical to Participate in 17th Annual Barrington Research Virtual Fall Investment Conference

Rhea-AI Summary

Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced its participation in the 17th Annual Barrington Research Virtual Fall Investment Conference. The event is scheduled for Thursday, September 12, 2024, and will be held virtually.

During the conference, Lifecore's management team will engage in one-on-one meetings with investors. This participation provides an opportunity for the company to connect with potential investors and discuss its operations, strategies, and future prospects in the CDMO industry.

The announcement highlights Lifecore's commitment to investor relations and its efforts to maintain open communication with the financial community. By participating in such events, the company aims to increase its visibility among investors and provide insights into its business model and growth potential.

News Market Reaction – LFCR

+4.15%

+4.15% Session move

In the trading session that priced this news, LFCR gained 4.15%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHASKA, Minn., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the Company will participate in the upcoming 17^th Annual Barrington Research Virtual Fall Investment Conference. Lifecore management will participate in 1-on-1 investor meetings during the event, which is scheduled to take place virtually on Thursday, September 12, 2024.

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the Company, visit Lifecore’s website at www.lifecore.com.

FAQ

When is Lifecore Biomedical (LFCR) participating in the Barrington Research Virtual Fall Investment Conference?

Lifecore Biomedical (LFCR) is participating in the 17th Annual Barrington Research Virtual Fall Investment Conference on Thursday, September 12, 2024.

What type of meetings will Lifecore Biomedical (LFCR) management have during the conference?

Lifecore Biomedical (LFCR) management will participate in one-on-one investor meetings during the conference.

Is the Barrington Research Fall Investment Conference that Lifecore Biomedical (LFCR) is attending an in-person or virtual event?

The 17th Annual Barrington Research Fall Investment Conference that Lifecore Biomedical (LFCR) is attending is a virtual event.

What is Lifecore Biomedical's (LFCR) primary business focus?

Lifecore Biomedical (LFCR) is a fully integrated contract development and manufacturing organization (CDMO).